Abstract Number: 0764 • ACR Convergence 2022
No Impact of Prior DMARD Exposures on Mortality in US Veterans with Cancer Treated with Immune Checkpoint Inhibitors
Background/Purpose: Immune checkpoint inhibitor (ICI) use for the treatment of multiple cancers continues to expand. Data on ICI treatment in autoimmune disease is limited as…Abstract Number: 0831 • ACR Convergence 2022
Management of Hepatic Sarcoidosis, a Retrospective Analysis of Patients at a University Hospital
Background/Purpose: Sarcoidosis is a multisystem granulomatous disease which can affect the GI system in about 5-10% of cases, out of which 11-80% can have hepatic…Abstract Number: 1114 • ACR Convergence 2022
Computational Drug Repositioning and 3D Skin Models Identify EGFR and PI3K Inhibitors as Anti-fibrotic Targets for Systemic Sclerosis
Background/Purpose: Genome-wide analyses of gene expression in systemic sclerosis (SSc) skin biopsies have identified differential responses based on the mechanism of action of the therapy.…Abstract Number: 1287 • ACR Convergence 2022
Are the American College of Rheumatology’s Web-Based Patient Education Materials Easy for Patients to Read and Comprehend?
Background/Purpose: Patient education materials (PEMs), obtainable from online resources, can be accessed by patients and physicians and used to supplement the medical information provided by…Abstract Number: 1542 • ACR Convergence 2022
Exploratory Clinical Subgroup Clustering in Systemic Sclerosis – Results from the Indian Progressive Systemic Sclerosis Registry
Background/Purpose: Classification of systemic sclerosis (SSc) into subsets has been a challenge due to it's heterogeneity. This study attempts to identify SSc subsets based on…Abstract Number: 1742 • ACR Convergence 2022
Shared Epitope Allomorphs Directly Influence Antigen-specific T-cell Responses in RA
Background/Purpose: The products of rheumatoid arthritis (RA)-associated MHC class II risk alleles HLA-DRB1*04:01 and *04:04 (DR4) differ only by two amino acids in the peptide…Abstract Number: 2040 • ACR Convergence 2022
Metformin Improves Objective Measures of Dry Eyes and Focus Score in Sjögren′s Disease: A Retrospective Observational Study
Background/Purpose: Metformin (dimethyl biguanide, Met) is a widely used, first-line antidiabetic drug with AMPK-dependent anti-inflammatory and immunomodulatory effects. In vitro studies and human trials in…Abstract Number: 2274 • ACR Convergence 2022
Factors Associated with Disease Flare Following SARS-CoV-2 Vaccination in People with Inflammatory Rheumatic and Musculoskeletal Diseases – Results from the Physician-Reported EULAR Coronavirus Vaccine (COVAX) Registry
Background/Purpose: To investigate the frequency and factors associated with disease flare following vaccination against SARS-CoV-2 in people with inflammatory/autoimmune rheumatic and musculoskeletal diseases (I-RMD).Methods: The…Abstract Number: 0132 • ACR Convergence 2022
Pleuroparenchymal Fibroelastosis: A Special Clinical Situation in Patients with Interstitial Lung Disease Associated with Connective Tissue Diseases. Descriptive Study from a Referral Centre
Background/Purpose: Pleuroparenchymal fibroelastosis (PPFE) is a rare interstitial lung disease (ILD) that can be idiopathic or associated with a variety of different conditions, including connective…Abstract Number: 0335 • ACR Convergence 2022
Multiplexed Mass Cytometry of Cutaneous Lupus Erythematosus and Dermatomyositis Skin: An In-depth B Cell Directed Immunoprofile
Background/Purpose: Cutaneous lupus erythematosus (CLE) and dermatomyositis (DM) are both characterized histologically by interface dermatitis with a perivascular and periadnexal lymphocytic infiltrate, requiring clinical correlation…Abstract Number: 0599 • ACR Convergence 2022
Expansion of HLA-DR+CD45RAhi Non-lymphoid Cells in Patients with Rheumatoid Arthritis
Background/Purpose: In RA, aberrant lymphocytes can damage synovial joints and other organs. Antigen-presenting cells (APC) can activate lymphocytes and are considered critical to initiate immune…Abstract Number: 0710 • ACR Convergence 2022
Risk Factors Associated with COVID-19 Breakthrough Infection Among Patients with Systemic Autoimmune Rheumatic Diseases: A Cohort Study
Background/Purpose: Some patients with rheumatic disease on DMARDs may be at increased risk of poor response to SARS-CoV-2 vaccines and thus breakthrough COVID-19 infections. We…Abstract Number: 0765 • ACR Convergence 2022
The Impact of Immunomodulating Treatment on the Immunogenicity of COVID-19 Vaccines in Patients with Immune-mediated Inflammatory Rheumatic Diseases Compared to Healthy Controls. a Swedish Nationwide Study (COVID19-REUMA)
Background/Purpose: The aim of the study was to elucidate antibody responses after vaccination with two doses of COVID-19 vaccines in patients with inflammatory rheumatic diseases…Abstract Number: 0832 • ACR Convergence 2022
Anti-NOR 90 Antibodies: What Is the Clinical Significance in Rheumatic Inflammatory Conditions?
Background/Purpose: Anti-NOR 90 antibodies have been detected in inflammatory conditions, neoplastic diseases and even in healthy individuals. Despite numerous epidemiologic studies, large scale studies are…Abstract Number: 1121 • ACR Convergence 2022
Intricate Roles of Low Gene Copy Numbers for Complement C4, C4A Deficiency and HLA-DRB1*03 as Genetic Risk Factors for Myositis, Its Subgroups and Autoantibodies
Background/Purpose: Idiopathic inflammatory myopathies (IIM) are a group of autoimmune diseases characterized by autoantibodies plus infiltration of leukocytes into muscles and/or the skin, leading to…
- « Previous Page
- 1
- …
- 46
- 47
- 48
- 49
- 50
- …
- 80
- Next Page »